Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: Results of a clinical phase I/II trial

British Journal of Cancer

Volumn 89, Issue 7, 2003, Pages 1172-1179

  Yamanaka, R ^a   Abe, T ^b   Yajima, N ^a   Tsuchiya, N ^a   Homma, J ^a   Kobayashi, T ^a   Narita, M ^b   Takahashi, M ^b   Tanaka, R ^a  

^a NIIGATA UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

Author keywords

Dendritic cell; ELISPOT assay; Glioma; Immunotherapy

Indexed keywords

CANCER VACCINE; CD16 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CELL EXTRACT;

ADULT; AGED; ANAPLASTIC CARCINOMA; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; AUTOTRANSPLANTATION; CELL LYSATE; CELLULAR IMMUNITY; CERVICAL LYMPH NODE; CLINICAL ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DEVICE; DRUG PULSE THERAPY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; ERYTHEMA; EVALUATION; FEMALE; FEVER; GLIOBLASTOMA; GLIOMA; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INJECTION SITE; LYMPHEDEMA; LYMPHOCYTIC INFILTRATION; MALE; OMMAYA RESERVOIR; PERIPHERAL CIRCULATION; PERIPHERAL LYMPHOCYTE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; REOPERATION; SIDE EFFECT; T LYMPHOCYTE ACTIVATION;

ADULT; AGED; ANTIGENS, CD; BRAIN NEOPLASMS; CANCER VACCINES; CYTOKINES; DENDRITIC CELLS; FEMALE; GLIOMA; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOENZYME TECHNIQUES; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; VACCINATION;

EID: 0242329784     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601268     Document Type: Article

References (33)

1. Akasaki Y, Kikuchi T, Homma S, Abe T, Kofe D, Ohno T (2001) Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J Immunother 24: 106-113
2. Aoki H, Mizuno M, Natsume A, Tsugawa T, Tsujimura K, Takahashi T, Yoshida J (2001) Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor. Cancer Immunol Immunother 50: 463-468
3. Boczkowski D, Nair SK, Snyder D, Gilboa E (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184: 465-472
4. Chen Q, Daniel V, Maher DW, Hersey P (1994) Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer 56: 755-760
5. Constam DB, Philipp J, Malipiero UV, ten Dijke P, Schachner M, Fontana A (1992) Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J Immunol 148: 1404-1410
6. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte - macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539-3543
7. Fong L, Engleman EG (2000) Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18: 245-273
8. Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP (1999) Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 5: 2963-2970
9. Gong J, Avigan D, Chen DZ, Koido S, Kashiwaba M, Kufe D (2000) Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA 97: 2715-2718
10. Gong J, Chen D, Kashiwaba M, Kufe D (1997) Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 3: 558-561
11. Heimberger AB, Crotty LE, Archer GE, McLendon RE, Friedman A, Dranoff G, Bigner DD, Sampson JH (2000) Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol 103: 16-25
12. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2: 52-58
13. Inaba K, Inaba M, Naito M, Steinman RM (1993) Dendritic cell progenitors phagocytose particles, including Bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo. J Exp Med 178: 479-488
14. Insug O, Ku G, Ertl HC, Blaszczyk-Thurin M (2002) A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res 22: 613-621
15. Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T (2001) Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50: 337-344
16. Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Muller CA, Becker V, Gross AJ, Hemmerlein B, Kanz L, Muller GA, Ringert RH (2000) Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 6: 332-336
17. Liau LM, Black KL, Martin NA, Sykes SN, Bronstein JM, Jouben-Steele L, Mischel PS, Belldegrun A, Cloughesy TF (2000) Treatment of a glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogenic major histocompatibility complex class I-matched tumor peptides. Neurosurg Focus 9: Article 8
18. Liau LM, Black KL, Prins RM, Sykes SN, DiPatre PL, Cloughesy TF, Becker DP, Bronstein JM (1999) Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 90: 1115-1124
19. Macdonald DR, Cascino TL, Schold Jr SC, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7): 1277-1280
20. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, Lotze MT (1995) Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1: 1297-1302
21. Medawar PB (1948) Immunity to homologous grafted skin: III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 29: 58-69
22. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332
23. Ni HT, Spellman SR, Jean WC, Hall WA, Low WC (2001) Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neuro-oncol 51: 1-9
24. Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H (1999) Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res 59: 4035-4041
25. Sampson JH, Archer GE, Ashley DM, Fuchs HE, Hale LP, Dranoff G, Bigner DD (1996) Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc Natl Acad Sci USA 93: 10399-10404
26. Satoh J, Lee YB, Kim SU (1995) T-cell costimulatory molecules B7-1 (CD80) and B7-2 (CD86) are expressed in human microglia but not in astrocytes in culture. Brain Res 704: 92-99
27. Steinman RM, Pack M, Inaba K (1997) Dendritic cells in the T-cell areas of lymphoid organs. Immunol Rev 156: 25-37
28. Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL, Murphy GP (1998) Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36: 39-44
29. Witham TF, Erff ML, Okada H, Chambers WH, Pollack IF (2002) 7-Hydroxystaurosporine-induced apoptosis in 9L glioma cells provides an effective antigen source for dendritic cells and yields a potent vaccine strategy in an intracranial glioma model. Neurosurgery 50: 1327-1334
30. Yamanaka R, Yajima N, Abe T, Tsuchiya N, Homma J, Narita M, Takahashi M, Tanaka R (2003) Dendritic cell-based glioma immunotherapy (Review). Int J Oncol 23: 5-15
31. Yamanaka R, Yajima N, Tsuchiya N, Tanaka R, Ramsey J, Blease RM, Xanthopoulos KG (2002) Administration of interleukin-12 & -18 enhancing the antitumor immunity of genetically modified dendritic cells that had been pulsed with Semliki Forest virus mediated tumor complementary DNA. J Neurosurg 97: 1184-1190
32. Yamanaka R, Zullo SA, Tanaka R, Blaese M, Xanthopoulos KG (2001) Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA. J Neurosurg 94: 474-481
33. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, Yong WH, Incardona F, Thompson RC, Riedinger MS, Zhang W, Prins RM, Black KL (2001) Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61: 842-847